$BCRX
BIOCRYST PHARMACEUTICALS INC

2022 Q3 Form 10-Q Financial Statement

#000162828022021373 Filed on August 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $75.83M $65.53M $49.92M
YoY Change 84.97% 31.17% 161.94%
Cost Of Revenue $3.543M $246.0K $236.0K
YoY Change 499.49% -17.17% -96.02%
Gross Profit $72.28M $65.29M $49.69M
YoY Change 78.91% 31.46% 278.25%
Gross Profit Margin 95.33% 99.62% 99.53%
Selling, General & Admin $36.92M $38.02M $34.28M
YoY Change 5.51% 44.41% 55.02%
% of Gross Profit 51.07% 58.23% 69.0%
Research & Development $52.74M $61.99M $65.36M
YoY Change 5.54% 17.24% 54.02%
% of Gross Profit 72.96% 94.95% 131.54%
Depreciation & Amortization $389.0K $335.0K $317.0K
YoY Change 69.87% 70.05% 78.09%
% of Gross Profit 0.54% 0.51% 0.64%
Operating Expenses $89.66M $100.0M $99.64M
YoY Change 5.53% 26.27% 54.37%
Operating Profit -$17.45M -$34.72M -$49.96M
YoY Change -60.87% 17.38% -2.76%
Interest Expense $24.78M $24.02M $23.84M
YoY Change 75.52% 78.01% 84.73%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$41.00M -$58.00M -$73.92M
YoY Change -30.28% 34.27% 14.99%
Income Tax $1.522M $856.0K $279.0K
% Of Pretax Income
Net Earnings -$42.52M -$58.86M -$74.20M
YoY Change -27.69% 36.25% 15.42%
Net Earnings / Revenue -56.08% -89.82% -148.62%
Basic Earnings Per Share -$0.23 -$0.32 -$0.40
Diluted Earnings Per Share -$0.23 -$0.32 -$401.3K
COMMON SHARES
Basic Shares Outstanding 185.9M shares 185.6M shares 184.9M shares
Diluted Shares Outstanding 186.2M shares 185.6M shares 184.9M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $426.9M $417.5M $443.5M
YoY Change 113.86% 91.13% 84.5%
Cash & Equivalents $246.9M $272.6M $395.5M
Short-Term Investments $180.0M $144.9M $47.96M
Other Short-Term Assets $12.51M $12.50M $15.69M
YoY Change -5.7% 26.17% 58.45%
Inventory $27.02M $23.38M $16.14M
Prepaid Expenses
Receivables $42.61M $41.49M $36.42M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $509.0M $494.9M $511.7M
YoY Change 101.39% 86.17% 86.91%
LONG-TERM ASSETS
Property, Plant & Equipment $8.464M $8.702M $8.799M
YoY Change 8.11% 13.47% 25.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $34.33M $0.00 $0.00
YoY Change
Other Assets $6.797M $6.983M $7.207M
YoY Change 30.94% 83.14% 98.81%
Total Long-Term Assets $49.59M $15.69M $16.01M
YoY Change 280.9% 36.61% 50.15%
TOTAL ASSETS
Total Short-Term Assets $509.0M $494.9M $511.7M
Total Long-Term Assets $49.59M $15.69M $16.01M
Total Assets $558.6M $510.5M $527.7M
YoY Change 110.19% 84.12% 85.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.622M $12.02M $13.88M
YoY Change -56.22% 19.2% 2.6%
Accrued Expenses $69.27M $79.71M $63.58M
YoY Change 23.01% 63.46% 94.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $81.64M $95.39M $81.02M
YoY Change -38.9% -17.48% -19.94%
LONG-TERM LIABILITIES
Long-Term Debt $223.9M $144.5M $140.2M
YoY Change 69.53% 13.98% 13.98%
Other Long-Term Liabilities $5.968M $6.198M $6.457M
YoY Change 18.53% 51.17% 65.56%
Total Long-Term Liabilities $223.9M $144.5M $140.2M
YoY Change 69.53% 13.98% 13.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $81.64M $95.39M $81.02M
Total Long-Term Liabilities $223.9M $144.5M $140.2M
Total Liabilities $305.5M $239.9M $221.3M
YoY Change 15.0% -1.03% -1.33%
SHAREHOLDERS EQUITY
Retained Earnings -$1.383B -$1.341B -$1.282B
YoY Change 16.25% 18.54% 17.83%
Common Stock $1.864M $1.859M $1.856M
YoY Change 3.67% 4.03% 4.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$242.7M -$213.2M -$164.2M
YoY Change
Total Liabilities & Shareholders Equity $558.6M $510.5M $527.7M
YoY Change 110.19% 84.12% 85.54%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$42.52M -$58.86M -$74.20M
YoY Change -27.69% 36.25% 15.42%
Depreciation, Depletion And Amortization $389.0K $335.0K $317.0K
YoY Change 69.87% 70.05% 78.09%
Cash From Operating Activities -$32.44M -$27.76M -$77.80M
YoY Change 39.39% 9.23% 27.52%
INVESTING ACTIVITIES
Capital Expenditures -$175.0K -$244.0K -$406.0K
YoY Change -52.05% -69.95% 306.0%
Acquisitions
YoY Change
Other Investing Activities -$69.37M -$97.19M -$38.07M
YoY Change -955.13% -1927.3% -357.73%
Cash From Investing Activities -$69.54M -$97.44M -$38.47M
YoY Change -997.68% -2261.93% -362.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 76.33M 147.0K $7.356M
YoY Change 1498.09% -96.79% 153.66%
NET CHANGE
Cash From Operating Activities -32.44M -27.76M -$77.80M
Cash From Investing Activities -69.54M -97.44M -$38.47M
Cash From Financing Activities 76.33M 147.0K $7.356M
Net Change In Cash -25.66M -125.0M -$108.9M
YoY Change 138.65% 665.71% 150.65%
FREE CASH FLOW
Cash From Operating Activities -$32.44M -$27.76M -$77.80M
Capital Expenditures -$175.0K -$244.0K -$406.0K
Free Cash Flow -$32.27M -$27.51M -$77.39M
YoY Change 40.85% 11.84% 27.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000882796
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
000-23186
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Registrant Name
EntityRegistrantName
BIOCRYST PHARMACEUTICALS, INC.
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
62-1413174
dei Entity Address Address Line1
EntityAddressAddressLine1
4505 Emperor Blvd., Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Durham
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27703
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
859-1302
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
BCRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1448000 usd
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
185945016 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
272571000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
504389000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
3345000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
144912000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
3212000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
41491000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29413000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
23378000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
15791000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11053000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9986000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
494853000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
566136000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8702000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8714000 usd
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
0 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
6829000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6983000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6472000 usd
CY2022Q2 us-gaap Assets
Assets
510538000 usd
CY2021Q4 us-gaap Assets
Assets
588151000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12024000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
27808000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79711000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72670000 usd
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1521000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1421000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2134000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1819000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
95390000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
103718000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6198000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5962000 usd
CY2022Q2 bcrx Future Royalties Payable
FutureRoyaltiesPayable
477666000 usd
CY2021Q4 bcrx Future Royalties Payable
FutureRoyaltiesPayable
449375000 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
144516000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
136082000 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
185876000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
185876000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
184350000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184350000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1859000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1843000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
482000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1125453000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1098498000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
177000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1340559000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1207504000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-213232000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-106986000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
510538000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
588151000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
65532000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
49959000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
115455000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
69018000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
246000 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
297000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6220000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61990000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52873000 usd
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-163000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58003000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
127350000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95308000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38017000 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26325000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72299000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48439000 usd
CY2022Q2 bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
1000 usd
CY2021Q2 bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
46000 usd
bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
3000 usd
bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
10000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
100254000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
79541000 usd
us-gaap Costs And Expenses
CostsAndExpenses
200134000 usd
us-gaap Costs And Expenses
CostsAndExpenses
149977000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-34722000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29582000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-84679000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-80959000 usd
CY2022Q2 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
609000 usd
CY2021Q2 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
13000 usd
bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
663000 usd
bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
39000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
24022000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
13495000 usd
us-gaap Interest Expense
InterestExpense
47859000 usd
us-gaap Interest Expense
InterestExpense
26399000 usd
CY2022Q2 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
132000 usd
CY2021Q2 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-134000 usd
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-45000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43198000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-131920000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-107482000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
856000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1135000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-58859000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43198000 usd
us-gaap Net Income Loss
NetIncomeLoss
-133055000 usd
us-gaap Net Income Loss
NetIncomeLoss
-107482000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
104000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-92000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
182000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
86000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-275000 usd
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
34000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
12343000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
18976000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-344000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59030000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43293000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-133217000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-107398000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185605000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
178127000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185605000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178127000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185253000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185253000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
177737000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177737000 shares
us-gaap Net Income Loss
NetIncomeLoss
-133055000 usd
us-gaap Net Income Loss
NetIncomeLoss
-107482000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
652000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
377000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
19468000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13111000 usd
bcrx Noncash Interest Expense And Amortization Of Debt Issuance Costs
NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts
36725000 usd
bcrx Noncash Interest Expense And Amortization Of Debt Issuance Costs
NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts
22664000 usd
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
-88000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7589000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2809000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1050000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8463000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
20089000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-135910000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2743000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3547000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
186000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
403000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-105557000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86422000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
650000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
912000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
139260000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
4000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19177000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7503000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7474000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7503000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7474000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
249000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-233715000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-59686000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
507734000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
274348000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
274019000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
214662000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-106986000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-74196000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
9000 usd
us-gaap Advertising Expense
AdvertisingExpense
8079000 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
115000 shares
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1504000 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1108000 shares
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5853000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9601000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-164215000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-58859000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-171000 usd
CY2022Q2 bcrx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
253000 shares
CY2022Q2 bcrx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3000 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
51000 shares
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
145000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9865000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-213232000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-19262000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-64284000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
179000 usd
CY2021Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
193000 shares
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
723000 usd
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
593000 shares
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2177000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5479000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-74988000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43198000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-95000 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1056000 shares
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4574000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7632000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-106075000 usd
CY2022Q2 us-gaap Advertising Expense
AdvertisingExpense
4095000 usd
CY2021Q2 us-gaap Advertising Expense
AdvertisingExpense
1800000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
bcrx Long Term Investment Maturity Minimum
LongTermInvestmentMaturityMinimum
P12M
us-gaap Advertising Expense
AdvertisingExpense
3204000 usd
bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
-211000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
69018000 usd
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
24022000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
47859000 usd
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
13495000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
26399000 usd
CY2022Q2 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
-172000 usd
bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
-339000 usd
CY2021Q2 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
-154000 usd
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23090000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25877000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27419000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25871000 shares
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
65532000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
49959000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
115455000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
145165000 usd
CY2022Q2 bcrx Available For Sale Debt Securities Accrued Interest
AvailableForSaleDebtSecuritiesAccruedInterest
190000 usd
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
-1000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
445000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
144912000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9989000 usd
CY2021Q4 bcrx Available For Sale Debt Securities Accrued Interest
AvailableForSaleDebtSecuritiesAccruedInterest
65000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10041000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
23378000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
15791000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
144912000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3212000 usd
CY2022Q2 bcrx Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two
DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
0 usd
CY2021Q4 bcrx Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two
DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
6829000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
144912000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10041000 usd
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
1843000 usd
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1980000 usd
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
5276000 usd
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5658000 usd
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
15616000 usd
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
9669000 usd
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2739000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
709000 usd
CY2022Q2 us-gaap Inventory Gross
InventoryGross
23631000 usd
CY2021Q4 us-gaap Inventory Gross
InventoryGross
16036000 usd
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
253000 usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
245000 usd
CY2021Q4 bcrx Future Royalties Payable
FutureRoyaltiesPayable
449375000 usd
CY2021Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
34000 usd
CY2022Q1 bcrx Non Cash Interest Expense On Royalty Financing Obligation
NonCashInterestExpenseOnRoyaltyFinancingObligation
19649000 usd
CY2022Q1 bcrx Royalties Revenues Paid And Payable
RoyaltiesRevenuesPaidAndPayable
-4765000 usd
CY2022Q1 bcrx Future Royalties Payable
FutureRoyaltiesPayable
464225000 usd
CY2022Q2 bcrx Non Cash Interest Expense On Royalty Financing Obligation
NonCashInterestExpenseOnRoyaltyFinancingObligation
19706000 usd
CY2022Q2 bcrx Royalties Revenues Paid And Payable
RoyaltiesRevenuesPaidAndPayable
-6265000 usd
CY2022Q2 bcrx Future Royalties Payable
FutureRoyaltiesPayable
477666000 usd
CY2022Q2 bcrx Aggregate Lease Expense
AggregateLeaseExpense
626000 usd
CY2021Q2 bcrx Aggregate Lease Expense
AggregateLeaseExpense
461000 usd
bcrx Aggregate Lease Expense
AggregateLeaseExpense
1220000 usd
bcrx Aggregate Lease Expense
AggregateLeaseExpense
913000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1181000 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y2M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.112
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2134000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1819000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6198000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5962000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
8332000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7781000 usd
CY2022Q2 bcrx Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
3440000 usd
CY2021Q4 bcrx Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
2626000 usd
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
607000 usd
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
379000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
819000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1265000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2266000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1717000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1373000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
617000 usd
CY2022Q2 bcrx Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
6734000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13972000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5640000 usd
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
115000 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
193000 shares
CY2020Q2 bcrx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
500000000 usd
CY2022Q2 bcrx Share Based Payment Arrangement Number Of Plans
ShareBasedPaymentArrangementNumberOfPlans
3 plan
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19468000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13111000 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
104406000 usd
CY2022Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear
20395000 usd
CY2022Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear
34794000 usd
CY2022Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
30343000 usd
CY2022Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
18002000 usd
CY2022Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
872000 usd

Files In Submission

Name View Source Status
0001628280-22-021373-index-headers.html Edgar Link pending
0001628280-22-021373-index.html Edgar Link pending
0001628280-22-021373.txt Edgar Link pending
0001628280-22-021373-xbrl.zip Edgar Link pending
bcrx-20220630.htm Edgar Link pending
bcrx-20220630.xsd Edgar Link pending
bcrx-20220630xexx311.htm Edgar Link pending
bcrx-20220630xexx312.htm Edgar Link pending
bcrx-20220630xexx321.htm Edgar Link pending
bcrx-20220630xexx322.htm Edgar Link pending
bcrx-20220630_cal.xml Edgar Link unprocessable
bcrx-20220630_def.xml Edgar Link unprocessable
bcrx-20220630_htm.xml Edgar Link completed
bcrx-20220630_lab.xml Edgar Link unprocessable
bcrx-20220630_pre.xml Edgar Link unprocessable
exhibit10.htm Edgar Link pending
exhibit10001.jpg Edgar Link pending
exhibit103.htm Edgar Link pending
exhibit104.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending